Varda Space Industries is partnering with United Therapeutics to pioneer pharmaceutical production in orbit, leveraging microgravity's unique molecular assembly properties. The collaboration capitalizes on reduced launch costs from SpaceX's Transporter missions and advances in space-accessible research infrastructure. By testing drug candidates in Earth's orbit, the companies aim to achieve more uniform crystalline structures that improve medication efficacy and stability.

Microgravity enables slower, more consistent molecular formation, creating uniform crystals rather than varied structures. This translates to pharmaceuticals with better dissolution rates, extended shelf life, and reduced storage requirements. Varda's 10,000-square-foot lab in El Segundo, California, will screen compounds before sending top candidates to space aboard their W-6 spacecraft currently in orbit.

The company has raised $330 million and operates 200 employees, with plans to launch seven missions next year after three planned launches this year. Varda's ultimate goal isn't building spacecraft—it's becoming a pharmaceutical company that uses space as a production environment. The reentry systems exist to bring valuable drug compounds back to Earth, not just to showcase space technology.

This shift represents the maturation of commercial space from experimentation to industrial-scale manufacturing, where orbital conditions become a competitive advantage for high-value pharmaceuticals.